Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Primary purpose
Allocation
Interventional model
Masking
4,220 participants in 2 patient groups
Loading...
Central trial contact
Stemline Trials
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal